Partial liquid ventilation (PLV) treatment severe cases of COVID-19

grabcad

Everyone: I'm offering some advice, the main reason for the shortage of ventilators is that the number of patients has skyrocketed, causing a squeeze on medical resources. The other factor is that the current high-flow oxygen treatment scheme has a low rescue success rate. Therefore, we propose using the liquid medium ventilation used to treat premature infants for severe and critical COVID-19 cases. From literature research, liquid ventilation can help increase oxygen absorption by clearing mucus blockages, improving gas exchange/ blood flow ratio, and improving oxygenation status. Local anti-inflammatory effects occur in vitro, inhibiting lung macrophage responses to foreign substances. In severe and critical COVID-19 patients, their lungs are occupied by a frozen secretion caused by the virus, resulting in complete loss of respiratory function, and high-pressure oxygen schemes cannot remove mucus, often worsening the condition. The liquid medium ventilation treatment scheme uses PFC as the ventilatory medium, introducing it into the lungs through nebulization or vaporization to intervene in respiratory failure. Specific methods include using a heat exchanger with a humidifier to give hot vapor inhalation of PFC through the respirator's inspiratory tube for 2 hours, then continuing regular mechanical ventilation for 6 hours. To improve treatment efficacy, comprehensive adoption of strategies such as lung-protective ventilation, lung re-expansion, and prone-position ventilation is recommended. If clinical treatment is effective, it will greatly increase the utilization rate of ventilators and partially solve the ventilator shortage problem.